Aurobindo Pharma has got the final approval from the USDFA for manufacturing and marketing Sevelamer Carbonate tablets in the American market.

Aurobindo Pharma has said in a BSE filing that “The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg.”

This product which is a therapeutic equivalent generic version of Genzyme’s Renvela tablets, is being launched immediately.

Read EquityPandit’s Technical Analysis on Nifty Pharma